Groupama Asset Managment Has $5.06 Million Stock Holdings in Amgen Inc. $AMGN

Key Points

• Groupama Asset Management has reduced its stake in Amgen Inc. by 5.6%, currently holding 16,499 shares valued at approximately $5.06 million.
• Significant changes in institutional investment for Amgen have been reported, including new purchases and substantial increases from firms like First Pacific Financial and Global Wealth Strategies & Associates.
• Amgen recently announced a quarterly dividend of $2.38 per share, marking an annualized dividend payout of $9.52 and a yield of 3.2%.

Groupama Asset Managment reduced its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,499 shares of the medical research company's stock after selling 981 shares during the quarter. Groupama Asset Managment's holdings in Amgen were worth $5,064,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. JT Stratford LLC boosted its holdings in shares of Amgen by 32.1% in the 1st quarter. JT Stratford LLC now owns 1,466 shares of the medical research company's stock worth $457,000 after acquiring an additional 356 shares in the last quarter. Sumitomo Mitsui Financial Group Inc. increased its holdings in shares of Amgen by 10.3% in the first quarter. Sumitomo Mitsui Financial Group Inc. now owns 61,643 shares of the medical research company's stock valued at $19,205,000 after purchasing an additional 5,775 shares in the last quarter. bLong Financial LLC increased its holdings in shares of Amgen by 5.1% in the first quarter. bLong Financial LLC now owns 3,100 shares of the medical research company's stock valued at $966,000 after purchasing an additional 150 shares in the last quarter. Texas Capital Bancshares Inc TX acquired a new stake in shares of Amgen in the first quarter valued at approximately $229,000. Finally, Texas Capital Bank Wealth Management Services Inc increased its holdings in shares of Amgen by 32.1% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 2,582 shares of the medical research company's stock valued at $805,000 after purchasing an additional 628 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company's stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The disclosure for this sale can be found here. 0.76% of the stock is owned by insiders.

Amgen Stock Down 0.7%

AMGN stock traded down $2.04 during mid-day trading on Friday, hitting $293.72. 1,643,970 shares of the company were exchanged, compared to its average volume of 2,104,120. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market cap of $158.13 billion, a P/E ratio of 24.02, a P/E/G ratio of 2.53 and a beta of 0.49. The firm's 50 day simple moving average is $293.43 and its 200 day simple moving average is $293.17. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $339.17.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period last year, the company posted $4.97 EPS. The business's quarterly revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 annualized dividend and a dividend yield of 3.2%. Amgen's payout ratio is 77.84%.

Analysts Set New Price Targets

A number of analysts recently weighed in on AMGN shares. William Blair reissued an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $305.00 target price on shares of Amgen in a report on Tuesday, June 24th. Guggenheim assumed coverage on shares of Amgen in a report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Finally, UBS Group decreased their price objective on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $303.76.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.